FREE Biopharma Daily Stock Updates - 02/17/21

Want to access our searchable database of catalysts and companies? Get access to BiopharmIQ for 30 days free, no credit card required. Check it out here!

$XBI $160.72 +1% 📈


Covid Updates

$RDHL +4% First patient dosed in ph 2/3 study of RHB-107. source


Pipeline Updates


$NKTR +13% Collaboration with SFJ Pharma for up to $150M to support registrational phase 2/3 trial of BEMPEG + KEYTRUDA in patients with head and neck cancer whose tumors express PD-L1. source


$VTVT +7% Phase 1 initiation of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis. source


$MYOV +4% Phase 3 LIBERTY study of Relugolix published in NEJM. source


$BPMC +8% sNDA accepted accepted for AYVAKIT for advanced systemic mastocytosis (SM). The FDA granted priority review and set a PDUFA target action date of June 16, 2021. source


Financial Updates


$MTEM -1% Offering


$YMAB -9% Offering


0 comments